Evidence map›Paper›PMID 34137815›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022

Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center.

Karen B Jacobson, Benjamin A Pinsky, Maria E Montez Rath, Hannah Wang, Jacob A Miller, Mehdi Skhiri, John Shepard, Roshni Mathew, Grace Lee, Bryan Bohman and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Review
  8. Article
  9. Death Reporting in Breakthrough and Unvaccinated SARS-CoV-2 Infection Cases.Disaster medicine and public health preparedness · 2023
    Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. COVID Infections Breakthrough Post-Vaccination: Systematic Review.Journal of pharmacy & bioallied sciences · 2022
    Article
  16. Article
  17. Article
  18. SARS-CoV-2 Mutations and their Viral Variants.Cytokine & growth factor reviews · 2022
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Karen B JacobsonDepartment of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California, USA.
Benjamin A PinskyDepartment of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California, USA.ORCID 0000-0001-8751-4810
Maria E Montez RathDepartment of Medicine, Division of Nephrology, Stanford University School of Medicine, Stanford, California, USA.
Hannah WangDepartment of Pathology, Stanford University School of Medicine, Stanford, California, USA.ORCID 0000-0002-3712-9188
Jacob A MillerDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA.
Mehdi SkhiriDepartment of Medicine, Primary Care and Population Health, Stanford University School of Medicine, Stanford, California, USA.
John ShepardDepartment of Quality, Patient Safety and Clinical Effectiveness, Stanford Health Care, Stanford, California, USA.
Roshni MathewDepartment of Pediatrics, Division of Infectious Diseases, Stanford University School of Medicine, Stanford, California, USA.
Grace LeeDepartment of Pediatrics, Division of Infectious Diseases, Stanford University School of Medicine, Stanford, California, USA.
Bryan BohmanWorkforce Health and Wellness, Stanford University School of Medicine, Stanford, California, USA.
Julie ParsonnetDepartment of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California, USA.
Marisa HolubarDepartment of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California, USA.ORCID 0000-0002-7585-1809

Funding

Global Epidemiology of Infectious DiseasesT32AI052073 · NIAID · STANFORD UNIVERSITY · PI Angelle Desiree LaBeaud, Stephen Patrick Luby · 2003 to 2026
$4.2M
NIAID NIH HHS T32 AI052073
6 · The paper itself

Abstract

backgroundAlthough mRNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines report >90% efficacy, breakthrough infections occur. Little is known about their effectiveness against SARS-CoV-2 variants, including the highly prevalent B.1.427/B.1.429 variant.

methodsIn this quality improvement project, we collected demographic and clinical information from post-vaccine SARS-CoV-2 cases (PVSCs), defined as healthcare personnel (HCP) with positive SARS-CoV-2 nucleic acid amplification test after receiving ≥1 vaccine dose. Available specimens were tested for L452R, N501Y, and E484K mutations using reverse-transcription polymerase chain reaction. Mutation prevalence was compared among unvaccinated, early post-vaccinated (≤14 days after dose 1), partially vaccinated (positive test >14 days after dose 1 and <14 days after dose 2), and fully vaccinated (>14 days after dose 2) PVSCs.

resultsFrom December 2020 to April 2021, ≥23 090 HCP received ≥1 dose of an mRNA-based SARS-CoV-2 vaccine, and 660 HCP cases of SARS-CoV-2 occurred, of which 189 were PVSCs. Among the PVSCs, 114 (60.3%), 49 (25.9%), and 26 (13.8%) were early post-vaccination, partially vaccinated, and fully vaccinated, respectively. Of 261 available samples from vaccinated and unvaccinated HCP, 103 (39.5%), including 42 PVSCs (36.5%), had the L452R mutation presumptive of B.1.427/B.1.429. When adjusted for community prevalence of B.1.427/B.1.429, PVSCs did not have significantly elevated risk of B.1.427/B.1.429 compared with unvaccinated HCP.

conclusionsMost PVSCs occurred prior to expected onset of full, vaccine-derived immunity. Presumptive B.1.427/B.1.429 was not more prevalent in post-vaccine cases than in unvaccinated SARS-CoV-2 HCP. Continued infection control measures, particularly <14 days post-vaccination, and continued variant surveillance in PVSCs are imperative to control future SARS-CoV-2 surges.

Indexed as

COVID-19SARS-CoV-2Academic Medical CentersCOVID-19 VaccinesDelivery of Health CareHumansIncidenceVaccinationCOVID-19 VaccinesB.1.427/B.1.429breakthrough COVID-19L452Rpost-vaccination SARS-CoV-2SARS-CoV-2 variant

Identifiers

PMID34137815
PMCPMC8344553

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.